Please enable JS

Investors & Media

SEC Filings

Form 424B5
CRISPR THERAPEUTICS AG filed this Form 424B5 on 01/05/2018
Document Outline
Entire Document (850 KB)
Subdocument 1 - 424B5 - 424B5
Page 1 - Filed pursuant to Rule 424(b)(5)
Page 2 - TABLE OF CONTENTS
Page 3 - ABOUT THIS PROSPECTUS SUPPLEMENT
Page 4 - WHERE YOU CAN FIND MORE INFORMATION
Page 5 - CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 6 - N/A
Page 7 - PROSPECTUS SUPPLEMENT SUMMARY
Page 8 - Hematopoietic Programs
Page 9 - Other Hematopoietic Programs
Page 10 - Other Immuno-oncology Programs
Page 11 - Implications of Being an Emerging Growth Company
Page 12 - THE OFFERING
Page 13 - N/A
Page 14 - RISK FACTORS
Page 15 - N/A
Page 16 - We Have A Limited Operating History, Which May Make It Difficult To Evaluate Our Technology And Prod
Page 17 - N/A
Page 18 - Our CRISPR/Cas9 Gene Editing Product Candidates Are Based On A New Gene Editing Technology, Which Ma
Page 19 - The FDA, The NIH And The EMA Have Demonstrated Caution In Their Regulation Of Gene Therapy Treatment
Page 20 - If We Experience Delays Or Difficulties In The Enrollment Of Patients In Clinical Trials, Our Receip
Page 21 - Positive Results From Early Preclinical Studies Of Our Product Candidates Are Not Necessarily Predic
Page 22 - We May Never Obtain FDA Approval For Any Of Our Product Candidates In The United States, And Even If
Page 23 - Adverse Public Perception Of Gene Editing And Cellular Therapy Products May Negatively Impact Demand
Page 24 - If, In The Future, We Are Unable To Establish Sales And Marketing Capabilities Or Enter Into Agreeme
Page 25 - Any Product Candidate For Which We Obtain Marketing Approval Could Be Subject To Restrictions Or Wit
Page 26 - The Commercial Success Of Any Of Our Product Candidates Will Depend Upon Its Degree Of Market Accept
Page 27 - Even If We Are Able To Commercialize Any Product Candidates, Such Products May Become Subject To Unf
Page 28 - Risks Related to Our Relationships with Third Parties
Page 29 - Our Collaborators And Strategic Partners May Control Aspects Of Our Clinical Trials and Commercializ
Page 30 - We Expect To Rely On Third Parties To Conduct Our Clinical Trials And Certain Aspects Of Our Preclin
Page 31 - We Expect To Rely On Third Parties To Manufacture Our Clinical Product Supplies, And We Intend To Re
Page 32 - N/A
Page 33 - Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business
Page 34 - Our Employees, Principal Investigators, Consultants And Commercial Partners May Engage In Misconduct
Page 35 - Product Liability Lawsuits Against Us Could Cause Us To Incur Substantial Liabilities And Could Limi
Page 36 - Our Business Is Subject To Economic, Political, Regulatory And Other Risks Associated With Internati
Page 37 - Risks Related to Intellectual Property
Page 38 - We Are Required To Pay Royalties Under Our License Agreements With Third-Party Licensors, And We Mus
Page 39 - N/A
Page 40 - The Intellectual Property That Protects Our Core Gene Editing Technology Is Jointly Owned, And Our L
Page 41 - We May Not Be Successful In Obtaining Necessary Rights To Any Product Candidates We May Develop Thro
Page 42 - The Intellectual Property Landscape Around Gene-Editing Technology, Including CRISPR/Cas9, Is Highly
Page 43 - Obtaining And Maintaining Our Patent Protection Depends On Compliance With Various Procedural, Docum
Page 44 - Changes To The Patent Law In The United States And Other Jurisdictions Could Diminish The Value Of P
Page 45 - Myriad
Page 46 - We May Be Subject To Claims That Our Employees, Consultants, Or Advisors Have Wrongfully Used Or Dis
Page 47 - We Have Broad Discretion In How We Use The Proceeds Of This Offering And May Not Use These Proceeds
Page 48 - We Are An Emerging Growth Company, And The Reduced Disclosure Requirements Applicable To Emerging Gr
Page 49 - If You Purchase Our Common Shares In This Offering, You Will Incur Immediate And Substantial Dilutio
Page 50 - The Market Price Of Our Common Shares May Be Adversely Affected By Market Conditions Affecting The S
Page 51 - Kapitaleinlagen
Page 52 - Certain U.S. Shareholders May Suffer Adverse Tax Consequences If We Are Characterized As A Passive F
Page 53 - U.S. Shareholders May Not Be Able To Obtain Judgments Or Enforce Civil Liabilities Against Us Or Our
Page 54 - USE OF PROCEEDS
Page 55 - DILUTION
Page 56 - N/A
Page 57 - PRICE RANGE OF COMMON SHARES
Page 58 - DIVIDEND POLICY
Page 59 - UNDERWRITING
Page 60 - N/A
Page 61 - European Economic Area
Page 62 - Canada
Page 63 - Japan
Page 64 - TAXATION
Page 65 - Swiss Cantonal and Communal Private Wealth Tax and Capital Taxes
Page 66 - Material U.S. Federal Income Tax Considerations to U.S. Holders
Page 67 - Distributions
Page 68 - Sale, Exchange or Other Taxable Disposition of the Common Shares
Page 69 - N/A
Page 70 - Backup Withholding and Information Reporting
Page 71 - LEGAL MATTERS
Page 72 - PROSPECTUS
Page 73 - TABLE OF CONTENTS
Page 74 - ABOUT THIS PROSPECTUS
Page 75 - CRISPR THERAPEUTICS AG
Page 76 - RISK FACTORS
Page 77 - SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 78 - RATIO OF EARNINGS TO FIXED CHARGES
Page 79 - USE OF PROCEEDS
Page 80 - Share Capital
Page 81 - Conditional Share Capital for Bonds and Similar Debt Instruments
Page 82 - Uncertificated Securities
Page 83 - Registration on Form S-3
Page 84 - COMPARISON OF SWISS LAW AND DELAWARE LAW
Page 85 - N/A
Page 86 - N/A
Page 87 - N/A
Page 88 - N/A
Page 89 - N/A
Page 90 - Transfer Agent And Registrar
Page 91 - DESCRIPTION OF DEBT SECURITIES
Page 92 - Conversion or Exchange Rights
Page 93 - Consolidation, Merger or Sale
Page 94 - Modification of Indenture; Waiver
Page 95 - Form, Exchange and Transfer
Page 96 - Payment and Paying Agents
Page 97 - DESCRIPTION OF WARRANTS
Page 98 - DESCRIPTION OF UNITS
Page 99 - Modification with Consent
Page 100 - Payments and Notices
Page 101 - DESCRIPTION OF OUR SUBSCRIPTION RIGHTS
Page 102 - PLAN OF DISTRIBUTION
Page 103 - N/A
Page 104 - LEGAL MATTERS
Page 105 - N/A
Page 106 - CRISPR Therapeutics AG
Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet